NetraMark HoldingsAINMF -4.35%22 EBITDA Margin % is -19,912.50% as of Mar. 2026. GuruFocus rates AINMF with a GF Score™ of 22/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, NetraMark Holdings ranks worse than 98.2% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. NetraMark Holdings's EBITDA for the
three
months ended in Mar. 2026 was $-1.59 Mil. NetraMark Holdings's Revenue for the
three
months ended in Mar. 2026 was $0.01 Mil. Therefore, NetraMark Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was -19,912.50%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
NetraMark Holdings EBITDA Margin % Related Terms
NetraMark Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for NetraMark Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AINMF vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, NetraMark Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NetraMark Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where NetraMark Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NetraMark Holdings (AINMF) has a EBITDA Margin % of -19,912.50% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NetraMark Holdings and its competitors. According to the industry distribution chart, NetraMark Holdings ranks #656 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 98.2%.
Is NetraMark Holdings' EBITDA Margin % too high?
NetraMark Holdings' current EBITDA Margin % is -19,912.50%. Based on the distribution chart, NetraMark Holdings ranks #656 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, NetraMark Holdings has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NetraMark Holdings' EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NetraMark Holdings ranks #656 out of 668 companies for EBITDA Margin %. This places NetraMark Holdings in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NetraMark Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NetraMark Holdings's current EBITDA Margin % is -19,912.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NetraMark Holdings stock overvalued right now?
Based on GuruFocus' analysis, NetraMark Holdings (AINMF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $0.42 — trading 100.2% above its estimated fair value. The current EBITDA Margin % is -19,912.50%. NetraMark Holdings' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NetraMark Holdings (AINMF), the current EBITDA Margin % is -19,912.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NetraMark Holdings (AINMF) Overvalued in 2026?
Based on GuruFocus' analysis, NetraMark Holdings stock appears to be overvalued.
The current stock price of $0.42 is trading 100.2% above its estimated GF Value™ of $0.21.
GuruFocus considers NetraMark Holdings to be Significantly Overvalued.
Key valuation signals for AINMF:
EBITDA Margin %: -19,912.50%
GF Value™: $0.21 vs. price of $0.42 (100.2% above fair value)
No single metric tells the full story. See the AINMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NetraMark Holdings Inc provides AI-powered insights and software solutions to optimize clinical trial design and outcomes for pharmaceutical sponsors. The company offers AI solutions to trial sponsors, CROs, and biotechnology companies across the globe. It earns revenue from its proprietary NetraAI platform, an advanced machine learning system purpose-built to analyze complex clinical trial data and identify meaningful patient subpopulations.
22GF Score
Get the complete analysis for AINMF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AINMF has been successfully added to your 
